Artelo Biosciences Q2 GAAP EPS of -0.56
ARTL Stock | USD 1.03 0.07 6.36% |
About 61% of Artelo Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Artelo Biosciences stock suggests that many investors are alarmed at this time. Artelo Biosciences' investing sentiment shows overall attitude of investors towards Artelo Biosciences.
Artelo |
Artelo Biosciences press release Q2 GAAP EPS of -0.56.As of June 30, 2023, the company had approximately 14.0 million in cash and investments, compared to 17.5 million as...
Read at seekingalpha.com
Artelo Biosciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Artelo Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Artelo Biosciences Fundamental Analysis
We analyze Artelo Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artelo Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artelo Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Artelo Biosciences is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Artelo Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Artelo Biosciences stock to make a market-neutral strategy. Peer analysis of Artelo Biosciences could also be used in its relative valuation, which is a method of valuing Artelo Biosciences by comparing valuation metrics with similar companies.
Peers
Artelo Biosciences Related Equities
AKTX | Akari Therapeutics | 8.04 | ||||
KTTA | Pasithea Therapeutics | 6.55 | ||||
ALRN | Aileron Therapeutics | 4.38 | ||||
MNOV | MediciNova | 2.99 | ||||
VCNX | Vaccinex | 2.44 | ||||
BPMUF | Basilea Pharmaceutica | 0.00 | ||||
BRIBF | Brii Biosciences | 0.00 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
CRIS | Curis | 1.35 | ||||
SLRX | Salarius Pharmaceuticals | 1.38 | ||||
ASCLF | Ascletis Pharma | 5.26 | ||||
NTRBW | Nutriband Warrant | 16.67 |
Check out Artelo Biosciences Hype Analysis, Artelo Biosciences Correlation and Artelo Biosciences Performance. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Return On Assets (0.54) | Return On Equity (0.89) |
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.